The acquired software as a service (SaaS) company, Cytobank, will provide cloud and machine learning-based software for single-cell data analysis, sharing, and archiving to Beckman Coulter’s clients.
Cytobank’s platform provides accelerated research productivity through high-dimensional multi-omics data analysis, visualization, and collaboration across multiple sites, according to the company.
Beckman Coulter Life Sciences’ a California-based biomedical testing manufacturer will tie in the capabilities gained from this acquisition to its CytoFLEX LX 21-color flow cytometer for additional high-complexity workflow and data analysis for clinical research scientists.
David Craford, president and CEO of Cytobank, told us that the company’s platform will enable Beckman’s customers to use machine learning-based analysis to approach their cytometric data more objectively and share their analyses with clinical research collaborators.
Cytobank will join Beckman Coulter Life Sciences through the Danaher Life Sciences platform, which has generated approximately $6.5bn of revenue in 2018 through the combined work of Beckman Coulter, SCIEX, Molecular Devices, Pall, and Leica Microsystems.